About: Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
Creator	Elmer, V Jun, Guo Lei, Zha Lingling, Pan Neil, French Villanueva,
source	PMC
abstract	BACKGROUND: Studies assessing the effect of high dose tigecycline on severe infections are limited and remain controversial. OBJECTIVES: To assess systematically the effectiveness and safety of high dose tigecycline in the treatment of severe infections. METHODS: Pubmed, Web of Science, Embase, MEDLINE, Cochrane Library and ClinicalTrials were searched up to February 20, 2019 for studies that compared the effectiveness and safety of high dose tigecycline with standard dose tigecycline or other non-tigecycline-containing regimens in the treatment of severe infections. Rates for all-cause mortality, clinical cure, microbiological eradication and adverse events were analysed. RESULTS: Ten studies with 593 patients were included. The results indicated that using high dose tigecycline resulted in better outcomes compared with controls with lower all-cause mortality (OR 0.44, 95% CI 0.30–0.66, p < 0.0001), higher clinical cure (OR 3.43, 95% CI 2.09–5.63, p < 0.00001), higher microbiological eradication (OR 2.25, 95% CI 1.44–3.50, p = 0.0003), and without increasing adverse events rates. Subgroup analysis showed that high dose tigecycline reduced all-cause mortality in nosocomial acquired pneumonia (OR 0.39, 95% CI 0.22–0.70, p = 0.002), bloodstream infections (OR 0.19, 95% CI 0.06–0.58, p = 0.004) and mixed infections (OR 0.20, 95% CI 0.07–0.59, p = 0.003), with no statistical differences in complicated intra-abdominal infections (OR 2.04, 95% CI 0.80–5.23, p = 0.14). In carbapenem-resistant pathogens, the microbiological eradication rate in those given high dose tigecycline did not differ from controls (OR 1.07, 95% CI 0.44–2.60, p = 0.87), although mortality was reduced (OR 0.20, 95% CI 0.09–0.45, p = 0.0001). The main limitation of the review is that most of the included studies are observational studies with small sample sizes and high risks of bias. CONCLUSIONS: High dose tigecycline treatment is effective and safe for severe infections owing to its lower all-cause mortality, higher clinical cure, microbiological eradication and comparable adverse events. However, as a result of the high risks of bias of the included studies, well-designed randomised clinical trials are warranted to establish the effectiveness and safety of high dose tigecycline compared with standard dose tigecycline and other commonly used antibiotics.
has issue date	2020-01-31(xsd:dateTime)
bibo:doi	10.1007/s12325-020-01235-y
bibo:pmid	32006240
has license	no-cc
sha1sum (hex)	343f33a90a77418ef4222f307452a077f9c05c66
schema:url	https://doi.org/10.1007/s12325-020-01235-y
resource representing a document's title	Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7223407
has PubMed identifier	32006240
schema:publication	Adv Ther
resource representing a document's body	covid:343f33a90a77418ef4222f307452a077f9c05c66#body_text
is schema:about of	named entity 'severe infections' named entity 'HIGH DOSE' named entity 'SEVERE' named entity 'TIGECYCLINE' named entity 'assessing' named entity 'Studies' named entity 'high dose' named entity 'high dose' named entity 'microbiological' named entity 'odds ratios' named entity 'meta-analysis' named entity 'renal injury' named entity 'tigecycline' named entity 'antibiotics' named entity 'tigecycline' named entity 'Cochrane Library' named entity 'Z-curve' named entity 'bloodstream infections' named entity 'VAP' named entity 'PROSPERO' named entity 'odds ratios' named entity 'intra-abdominal infections' named entity 'meta-analysis' named entity 'pharmacodynamic' named entity 'meta-analysis' named entity 'Physiology' named entity 'China' named entity 'antibiotics' named entity 'Cochrane Collaboration' named entity 'control group' named entity 'subgroup analysis' named entity 'adverse events' named entity 'tigecycline' named entity 'Cochrane Library' named entity 'RCT' named entity 'control event rate' named entity 'Publication bias' named entity 'Ethics' named entity 'statistical significance' named entity 'HAP' named entity 'bacteriostatic agent' named entity 'adverse events' named entity 'nosocomial infections' named entity 'meta-analysis' named entity 'carbapenem' named entity 'microbiological' named entity 'research project' named entity 'tigecycline' named entity 'signs of infection' named entity 'bloodstream infections' named entity 'loading dose' named entity 'tigecycline' named entity 'pathogens' named entity 'intra-abdominal infections' named entity 'tigecycline' named entity 'control group' named entity 'clinical outcomes' named entity 'carbapenem' named entity 'adverse events' named entity 'nausea' named entity 'Meta-Analyses' named entity 'statistically significant' named entity 'pathogens' named entity 'tetracycline' named entity 'severe infections' named entity 'tigecycline' named entity 'antibiotics' named entity 'Enterococcus faecium' named entity 'Gramnegative' named entity 'clinical practice' named entity 'odds ratios' named entity 'funnel plot' named entity 'odds ratios' named entity 'off-label' named entity 'serum' named entity 'synergistic effect'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software